Related Experiment Video
Updated: Jul 23, 2025

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
Nuclear Factor-κB is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease
1Clinical Research Institute, National Hospital Organization, Kyoto Medical Center Kyoto, Japan.
Insights
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling regulates inflammation and immunity. Inhibiting NF-κB shows therapeutic potential for cardiovascular diseases, diabetes, and inflammatory conditions.
Area of Science:
- Molecular Biology
- Immunology
- Pharmacology
Background:
- Nuclear factor kappa-light-chain-enhenser of activated B cells (NF-κB) is a key regulator of inflammatory and immune responses.
- NF-κB activation is implicated in the pathogenesis of cardiovascular diseases (CVDs), atherosclerosis, and diabetes.
Purpose of the Study:
- To review recent advances in understanding the NF-κB signaling pathway's role in inflammation, metabolism, and immunity.
- To explore the diagnostic and therapeutic potential of targeting NF-κB for various human diseases.
Main Methods:
- Literature review of studies on NF-κB signaling.
- Analysis of therapeutic agents and natural compounds that inhibit NF-κB.
- Discussion of immunoglobulin-free light chains as potential biomarkers.
Main Results:
- Therapeutic agents like pimobendan and SGLT2 inhibitors demonstrate anti-inflammatory effects via NF-κB inhibition.
- Pharmacological agents and natural compounds can inhibit NF-κB, offering treatment options for inflammatory diseases.
- Immunoglobulin-free light chains may serve as biomarkers for NF-κB activation and treatment efficacy.
Conclusions:
- Targeting the NF-κB pathway holds significant promise for developing novel diagnostics and therapeutics for inflammatory diseases, CVDs, and diabetes.
- Further research into NF-κB signaling can lead to improved management strategies for these conditions.
Abstract:
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is responsible for the regulation of genes involved in inflammation and immune responses. NF-κB may play an important role in cardiovascular diseases (CVDs), atherosclerosis and diabetes. Several therapeutic agents used for the treatment of CVDs and diabetes, such as pimobendan and sodium-glucose cotransporter 2 inhibitors, exert anti-inflammatory effects by inhibiting NF-κB activation; anti-inflammatory therapy may have beneficial effects in CVDs and diabetes. Several pharmacological agents and natural compounds may inhibit NF-κB, and these agents alone or in combination may be used to treat various inflammatory diseases. Immunoglobulin-free light chains could be surrogate biomarkers of NF-κB activation and may be useful for evaluating the efficacy of these agents. This review discusses recent advances in our understanding of how the NF-κB signalling pathway controls inflammation, metabolism and immunity, and how improved knowledge of these pathways may lead to better diagnostics and therapeutics for various human diseases.
More Related Videos
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Regulation of Nuclear Protein Sorting
Co-activators and Co-repressors

